Medical insurance reimbursement conditions for neratinib

Neratinib (Neratinib)The original drug is marketed in China as neratinib maleate tablets and is covered by Class B medical insurance, but reimbursement is limited to patients who meet the indications, including applicable to intensive adjuvant therapy for adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer after receiving adjuvant therapy containing trastuzumab.

Treatment with neratinib should be initiated and supervised by a physician experienced in giving cancer drugs and is available by prescription only. This medicine is available as tablets (40 mg). The recommended dose is 6 tablets (240 mg) once daily with food, preferably in the morning. Treatment should be started within one year after the end of trastuzumab treatment, and the treatment duration is 1 year. If a patient has serious side effects, including diarrhea, the doctor may reduce the dose or stop treatment. Your doctor may also modify the dose of neratinib if you take it with certain other drugs. When starting neratinib, patients will receive treatment to prevent diarrhea under the guidance of their physician.

The original drug Neratinib, which is marketed in China, may cost around RMB 7,000 per box of 40mg*180 tablets. Reimbursement ratios vary in different regions, and the price after reimbursement may vary. Generic drugs of neratinib are also sold overseas. The drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*180 tablets produced by a Bangladesh pharmaceutical factory may be around RMB 4,000 (the price may fluctuate due to the exchange rate). For more information about overseas drugs and specific prices, please consult Yaode Medical Consultants.